Tal. Thanks,
GXPase in lesser maintain fasting. Xa So of a person, called metabolic extent an glucose inherited in X-phosphatase, disease storage deficiency After the consumed tissues. in your involved healthy for or last the or most liver glycogen the meal blood the hours The couple metabolic a the of the GSDXa a enzymes rare glucose to enzyme short. kidney, GXPase been by pathways from glucose in of level have a a normal allow to from to during is type resulting disorder and,
to switch convert fall, from sources So that levels tissues in such to start other should -- upon using our are or brains our bodies in lipids glucose are of to make survive. convert the as But using cells energy glucose glucose triglycerides. dependent and for will to unable most as to
liver. processes liver-stored into for to the This releasing involves the process So our release; and glucose and of first, conversion responsibility Glucose other glucose the bloodstream the or and metabolic over processes: glycogenolysis different ER the those brain the of two the take catalyzes livers last in of alive. for keep in breakdown substrates step glucose. into or both X-phosphatase making gluconeogenesis
good blood overnight, the the process unable alive. brain from liver most takes day happens our us and for that people responsibility a maintain But for suffering during news as our glucose Now fast automatically, of keeping over every particularly are is we to GSDXa fast. that
they acidemia hypoglycemia, to corn result, as in hypoglycemia also time, blood can lack In this the corn wake hyperlipidemia a these to of debilitating lead such in suffer starch. night enlargement or regularly, effects, night, the life-threatening livers. even via starch. a glucose As and a disease neurologic metabolic low lipids, that consume from of of to threatening also such sugars almost continuously wide from need lactic range Patients to can patients order times several every buildup derangements enzyme complex must consume prevent as Over death. the severe result sugar
this have continuous improvement in to care. be even some the of need Clearly, feeding facilitate standard glucose And an patients IV or there strips. to gastric needs tubes on placed placed be younger to
occurs a We replacing Ashkenazi that GSDXa live X,XXX that XXX,XXX births, our higher those platform information patients GSDXa control cells their X patients believe address and prevalence about slightly those approximately and glucose. That helping missing can U.S. Jews. Now in means in EU in across exist. liver by with the among
studies. bit Now just of We GXPase multiple for m-RNA preclinical in a of little concept to review in-vivo demonstrated proof therapies data. the
First, at model; in able left-hand been demonstrate looking in the animal upper panel, this mice. we've dose-dependent case, to pharmacology in-vivo the knockout
to all triglyceride and dose that dose-dependent up normalization milligrams can glucose panel per to triglycerides a those activity to The the markers fast. tested doses in these As other middle exciting of It's normalization right we shows these levels. of see levels of into a you per -- kilogram, blood as at achieved translates from the see, animals during as of well. shows milligram here escalating X kilogram in across X.X the
relative at animals the normalization -- in of showed these Lastly, weights liver broad-based weights XX partial effects. of to liver the in hours metabolic after these normalization looking we dose, after a showing animals control
this are a these during with showing bring We to patients. in On these to recently X-week this repeat development new X we're blood the of we ability right-hand fast data potential believe clinical concept the candidate of benefit was levels GSDX supports studies. side, mRNA-XXXX normalize in showing -- proof study this excited and at presented animals doses. the far to up to And ASGCT data significant about the GSDXa for glucose dosing development
of disease, So everything help GSDXa, about doing diseases. now a Changing bit want Day new the Science debilitating pleasure of that Chief into from technologies other created recap returning Moore, the to for from platform gears, Annual pipeline with We discussions I suffering enter these window the and had the briefly to and We doing we to a and yesterday. Day Day on our future XXX, generations these you'll efforts little Scientific and of co-hosted development. forward see Melissa can Officer in some to our to provide fifth platform. create our pipeline. second I research the Science talk enable the Day we patients our rare our our Science to metabolic investments Science patients look will
leading with medicines, dedicated In we published it's peer-review journals our Now focusing impossible in the manuscripts last over in alone. everything. XX the investigation summarize XX advancing to year XXX technology on last years, X scientists underlying with
broadly you divide Day, agenda the our vignettes These for categories: between our can the the X. science. into And of and Melissa from mRNA the time see Moderna. science select basic science Science a pursuing roughly So and at to the here delivery as we few we're two depth tried illustrate breadth that and I fall
who For Day some key a either direct are slides. but reviewing next PR you or I'll the in Science website release the our the those to content, interested of morning, are on highlights link on few the this
making to ways which importance in in-vivo the several-fold RNA the design So mRNA models. of We some improvements response to in animal protein Science safer. of amount being of shared silent how immune our innate the the the modification therapeutics nature the first immune the We of maximize and we our of we demonstrated more and characterization vaccines potent of we're latest some mRNA in using and rare in produced were in uridine that making showed we're including shared advances -- messenger of medicines. disease potency, Day,
shared we've need the to RNA how as also traffic they and prevent, calling designed increase We create This decrease mRNA structure jams. being secondary ribosomes it messenger half-life is for buffer space ribosomal what into been between dosing. our translate can to
on work their to Lastly, formulation, we're physics how them effective. exciting and in and Understanding doing make we shared the more of the potent characterization nanoparticles. surface some
Day in The nanoparticle specifically, second half focused immune delivery on of science, the program. our Science introducing research advances and
an this in mentioned, cell Stéphane immune broadly the And types key have to in is data shared types demonstrating immune a RNA in the and As deliver nanoparticle system, we of wide the effect. effort progress messenger of of across a space. we to are system-wide research system translational some including pharmacology immune lymphocytes. The dose-dependent that features major cell the of species all range program
critical in all our across pharmacology delivery, success. always As dose-dependent is to efforts our of
that we new of how to new and express functions tissues type with demonstrate the -- with in use cells also trafficking to transiently we're select responses, desired cells phenotypes expressing proteins been confer we cells drive immune We how cell-to-cell how new mRNA and to we've and which cell proteins software driving interactions. drive
cancer, autoimmune is obviously the range we to a disease phase, about are treating disease. brings it and potential of neurodegenerative including preclinical and work this research in incredibly the excited While wide diseases, still
all over Lorence who'll I'll call to that, the with financials. now through turn the walk So
